Vitamin D Supplementation For Premenstrual Syndrome-Related Inflammation And Antioxidant Markers In Students With Vitamin D Deficient: A Randomized Clinical Trial
Notes for this study:
||(u/ml) TAC. Mean + SD. Placebo: before 19 ± 11, after 16 ± 12. Vitamin D: before 13 ± 2, after 21 ± 2.
|Number of Subjects
In a randomized, double-blind, placebo-controlled trial, 44 women with premenstrual syndrome and vitamin d deficiency (serum 25(OH)D levels 10–30 ng/mL) were allocated to take placebo or 50,000 IU of vitamin d every 2 weeks for 4 months. After 4 months, there was a greater reduction in PMS symptoms in the vitamin D group, the difference between groups being statistically significant. The vitamin D group also saw a greater reduction in IL-10, IL-12, and a greater increase in total antioxidant capacity, all of which were statistically significant compared with placebo.